R

Revolution Medicines

Clinical-stage oncology company developing RAS inhibitors

Director, Medical Affairs - GI

Biology & BiotechPosted on Nov 9
Full-timeTokyo, JapanNo salary listed

About the Job

Requirements

  • A minimum of 10 years of experience in Medical Affairs or related functions in the pharmaceutical or biotech industry.
  • A strong understanding of oncology clinical development, evidence generation, the treatment landscape, and strategic planning.
  • The ability to analyze and synthesize scientific information effectively.
  • Experience engaging with healthcare professionals, academic researchers, and medical societies in compliance with applicable rules.
  • Fluency in Japanese and business-level English.
  • Experience leading or supporting investigator-initiated or real-world evidence studies.
  • Willingness to travel up to 20% of the time.

Responsibilities

  • Develop and execute Japan medical strategy and medical objectives, including scientific engagement and communication, evidence generation, internal education, and patient advocacy activities.
  • Develop and execute a healthcare professional engagement strategy to gather insights that shape internal programs.
  • Act as the medical representative on cross-functional teams.
  • Serve as a therapeutic-area content expert.
  • Support routine gap assessments that inform development or refinement of publication strategy, evidence-generation plans, and the overall medical tactical plan.
  • Provide medical leadership in scientific engagement with key external stakeholders by organizing and leading advisory boards, investigator interactions, congress activities, and peer-to-peer discussions, and communicate resulting scientific insights to internal teams to inform strategy.
  • Communicate clinical and scientific data to key opinion leaders and other healthcare professionals through presentations, educational programs, and scientific discussions.
  • Represent Medical Affairs functions in cross-functional strategy meetings, including Clinical and Safety sub-teams, the Global Brand Team, the Global Product Team, Patient Advocacy, Market Access, and other strategic discussions.
  • Work with Clinical and MSL teams to provide enrollment, scientific, and engagement support so clinical trials meet study timelines.
  • Partner with RWE strategy and Biomarker/CDx teams on integrated evidence-generation strategies and activities as part of the GMA Plan.
  • Work with Patient Advocacy and Grants teams to incorporate the patient voice and define external medical education strategies for independent grants, respectively.
  • Provide medical support for scientific symposia and medical congresses, and collaborate across Medical Affairs functions to develop, review, and align scientific communication points and medical information response documents within legal and compliance guidelines.
  • Support review and approval of abstracts, manuscripts, corporate communications, and other data-disclosure documents, as well as internal stakeholder medical education activities concerning compound and competitor data.
  • Collaborate with regional and global stakeholders across Clinical Development and Operations, Commercial Operations, Program Management, Business Development, Regulatory, Safety, and Compliance.

Desired Qualifications

  • Advanced scientific or medical degree, such as MD, RPh, Ns, PhD, MPh, or MS.
  • Experience in gastrointestinal and pancreatic cancers and product launch in Japan.
  • A track record in publication planning, congress presentations, and scientific communications.

About the Company

Revolution Medicines

Clinical-stage oncology company developing RAS inhibitors

Revolution Medicines develops precision oncology drugs focused on cancers driven by RAS mutations. Its RAS(ON) inhibitors are small molecules that bind the active form of RAS to block cancer signaling, with candidates like Daraxonrasib (RMC-6236), Elironrasib (RMC-6291), and Zoldonrasib (RMC-9805) advancing in global Phase 3 trials. The company funds its research through collaborations, royalties, and upfront funding, and has not yet marketed a product. Its goal is to bring effective RAS-targeted therapies to patients and advance multiple candidates through late-stage trials toward approval, supported by strong cash reserves.

Company size
1,001-5,000
Company stage
IPO
Headquarters
Redwood City, CA
Founded
2014

Recently Posted Jobs

Explore more opportunities at Revolution Medicines

See more jobs